Trial Profile

An open-label phase I/II clinical trial designed to assess the safety, tolerability, efficacy and pharmacokinetics of ABSK141 in patients with advanced solid tumors

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jan 2026 New trial record
24 Dec 2025 According to an Abbisko Therapeutics media release, company announced that the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small-molecule KRAS G12D inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations.
01 Dec 2025 According to an Abbisko Therapeutics media release, company has cleared Investigational New Drug (IND) application for ABSK141, for the treatment of patients with advanced solid tumors harboring KRAS G12D mutations.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com